[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100138439":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":7,"locations":12,"responsibleParty":25,"collaborators":7,"id":27,"slug":28,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":32,"acronym":33,"eligibilityCriteria":34,"healthyVolunteers":29,"sex":35,"minAge":36,"maxAge":37,"enrollmentInfo":38,"targetDuration":7,"studyType":41,"phases":42,"briefSummary":44,"conditions":45,"keywords":47,"overallStatus":49,"whyStopped":7,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":58},{"fullName":5,"class":6},"Hospices Civils de Lyon","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Prospective cohort with an annual follow-up","Annualfollow-up including :\n\n* oral glucose tolerance test\n* dietary survey\n* biological evaluation\n* bacteriological and respiratory measures\n* dual-energy x-ray absorptiometry\n* physical activity survey",[13],{"facility":14,"status":7,"city":15,"state":7,"zip":16,"country":17,"countryCode":18,"cosmosGeoPoint":19,"geoPoint":24,"contacts":7},"Service de Médecine Interne - Centre Hospitalier Lyon Sud","Pierre-Bénite","69495","France","FR",{"type":20,"coordinates":21},"Point",[22,23],4.82424,45.70359,{"lat":23,"lon":22},{"type":26,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100138439","determination-of-the-predictive-factors-in-the-reversibility-or-the-aggravation-in-the-disorders-of-the-glucose-metabolism-in-cystic-fibrosis-patients-100138439",false,"NCT01072708","Determination of the Predictive Factors in the Reversibility or the Aggravation in the Disorders of the Glucose Metabolism in Cystic Fibrosis Patients","Determination of the Predictive Factors in the Reversibility or the Aggravation in the Disorders of the Glucose Metabolism in Cystic Fibrosis Patients (Study DIAMUCO)","DIAMUCO","Inclusion Criteria:\n\n* Cystic fibrosis patients with at least one visit in Cystic fibrosis Center in Rhône-Alpes (France) during the second half-year 2008\n* Patients with disorders or not of the glucose metabolism\n* Patient with pancreatic insufficiency\n\nExclusion Criteria:\n\n* Patient with hypoglycemia treatment : insulin or oral antidiabetic\n* Patient with an age \\\u003C 10 years\n* Patient with lung transplant","ALL","10 Years","65 Years",{"count":39,"type":40},230,"ACTUAL","INTERVENTIONAL",[43],"NA","For some years, the investigators observe an increase of the arisen of diabetes in cystic fibrosis patients However, this diabetes may be reversible. The investigators speak about \" Cystic fibrosis related diabetes.\". The objective of this project, is to know better what facilitates the appearance and the reversibility of the diabetes, such as the genetic mutations, the respiratory state and the lung infections. Theses knowledges should allow to adapt the screening of diabetes, and its treatment, for the patients affected by cystic fibrosis.",[46],"Diabetes in Cystic Fibrosis Patients",[48],"Cystic fibrosis -diabetes - glucose tolerance - reversibility - oral glucose tolerance test - predictive factors","COMPLETED","2025-08-27",{"date":52,"type":40},"2025-09-04",{"date":54,"type":7},"2009-04",{"date":56,"type":40},"2014-10",{"name":5,"class":6},1]